Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
52/100
Prion disease and Alzheimer disease (AD) are common causes of rapidly progressive dementia (RPD).
Why it matters
This case series and systematic review characterized patients with prion disease who were initially diagnosed as having rapidly progressive Alzheimer's disease, aiming to identify features and tests that support accurate diagnosis. It is about avoiding misdiagnosis and does not offer a treatment, cure, or prevention for Alzheimer's disease.
-
With the advancement of anti-amyloid treatments for Alzheimer disease, accurate assays for amyloid-β (Aβ) pathology are essential.
Why it matters
Seven of 9 plasma p-tau217 assays showed acceptable accuracy for detecting amyloid PET positivity, while 2 performed worse, and cutoff values did not transfer well between platforms. This means blood biomarker results may not be comparable across different test platforms.
-
Among 356 patients (79%) with AD as the primary suspected etiology, assessment of BBM classified 149 patients (42%) as high, 101 patients (28%) as intermediate, and 106 patients (30%) as low probability of AD.
Why it matters
This prospective diagnostic study looked at how a plasma biomarker panel of pTau181, GFAP, and NfL presented during multidisciplinary meetings related to syndrome diagnosis, suspected etiology, and clinician confidence in memory clinics. It is a cohort study of 450 patients, and the text provided does not state whether the panel changed diagnoses or confidence.
-
Increasing oily fish intake has been proposed as a strategy for Alzheimer's disease (AD) prevention, but evidence for long-term benefit remains limited.
Why it matters
This analysis of long-term fish intake found no clear protective effect on Alzheimer's disease risk over 21 years. It is observational, and the authors say the possible benefit seen in older participants during earlier follow-up needs more study.
-
Sleep spindles (SPs) and slow oscillations (SOs) are linked to cognition and neurodegeneration; however, their relationship with CSF orexin concentrations in symptomatic AD has not been characterized.
Why it matters
This prospective observational cohort study investigated whether non-rapid eye movement sleep spindles and slow oscillations relate to cerebrospinal fluid orexin and whether these features moderate links between orexin, cognition, neuropsychiatric symptoms, and Alzheimer's disease biomarkers. It explores sleep-related biology and does not provide a treatment, cure, or prevention.
-
This meta-analysis included cross-sectional amyloid PET scans acquired with 5 radiotracers from 49 227 participants across 53 studies from 15 countries (mean age, 71 years; 54% female, 62% cognitively impaired).
Why it matters
This large meta-analysis of amyloid PET scans from 49,227 participants found that positivity cutoffs converged around 18 Centiloids using a data-driven approach and 27 Centiloids for visual reads. The authors advise that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context.
-
Bacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis.
Why it matters
This is a protocol for an ongoing trial of Bacopa monnieri in people with amnestic mild cognitive impairment and early Alzheimer's disease. No results are available yet, so nothing can be concluded about its effects.
-
In Alzheimer's disease (AD), pathological tau protein shows a progressive accumulation of post-translational modifications (PTMs), reflecting disease severity, progression, and prion-like activity.
Why it matters
By mapping the molecular features of pathological tau across several dementias, this study identifies potential disease-specific biomarkers and therapeutic targets. It is laboratory-based and does not itself test any treatment, cure or prevention in patients.
-
Overall, these findings highlight the potential of EEG connectivity features for dementia classification and emphasize the importance of careful feature engineering and low-complexity models in the case of small-sample datasets.
Why it matters
EEG connectivity features showed potential for classifying Alzheimer's disease and frontotemporal dementia, but AD-FTD discrimination proved most challenging with overlapping network disruptions limiting separability. The findings emphasize the importance of careful feature engineering and low-complexity models for small-sample datasets.
-
Two independently constructed %p‐tau217 plasma clocks had strong correlations with actual time measures and were consistent across the two cohorts.
Why it matters
Using repeated blood measurements of the tau marker %p-tau217, researchers built a 'plasma clock' that estimates when a person first becomes biomarker-positive and may help predict when Alzheimer's symptoms begin. The authors suggest this approach may be useful for predicting symptom onset and for staging the disease biologically.
-
Blood biomarkers of Alzheimer's disease (AD) are promising for dementia prediction, but their association with progression across intermediate stages of cognitive decline in the general population remains unclear.
Why it matters
This population-based cohort study found that several blood biomarkers were associated with faster progression from mild cognitive impairment to dementia, while no biomarker was associated with developing mild cognitive impairment from normal cognition. It suggests biomarkers may help stratify risk at the mild cognitive impairment stage but does not test any treatment, cure, or prevention.
-
There have been 23 studies (completed or reported as ongoing) of multidomain interventions for AD, including 19 RCTs.
Why it matters
This review of 23 studies reports that most completed trials of multidomain therapy showed benefit in at least one arm and argues this approach should be standard care. It is a review of existing trials, not new evidence, and does not establish that multidomain therapy cures or prevents Alzheimer's disease.
-
The preanalytical delay has a significant impact for Aβ40 and Aβ42.
Why it matters
Delays in processing blood samples significantly affected Aβ40 and Aβ42, but the performance of p-tau217 and the p-tau217/Aβ42 ratio stayed similar. This supports the p-tau217/Aβ42 ratio as a robust marker for Alzheimer's diagnosis regardless of preanalytical delays.
-
In the within-language condition, combined speech timing and lexico-semantic features yielded maximal classification (area under the receiver operating characteristic curve [AUC]=0.88), outperforming single-feature models (AUC=0.79 for timing features; AUC=0.80 for lexico-semantic features).
Why it matters
This study tested automated speech analysis for distinguishing Alzheimer dementia and found that speech timing features worked well within one language and also generalized to Spanish speakers, while lexico-semantic features performed less well across languages. The authors say this supports developing clinically usable automated speech and language analysis tools, but it is a marker study, not a treatment or cure.
-
Early identification of Alzheimer's disease (AD) pathology is essential for timely intervention, particularly in primary care.
Why it matters
This study evaluated a stepwise framework combining brief cognitive screening, risk assessment, brain imaging, and plasma biomarkers to identify Alzheimer's disease pathology in primary care. It addresses diagnosis rather than treatment, cure, or prevention.
-
Accelerated atrophy of medial temporal lobe subregions was evident already during preclinical AD.
Why it matters
MRI atrophy markers detected abnormal shrinkage in medial temporal lobe subregions already during preclinical Alzheimer's disease, and the best marker differed by disease stage and intended use. This is about improving detection and staging, not about treating, curing, or preventing the disease.
-
52/100
This study evaluates the efficacy, safety, and economics of galantamine in the treatment of Alzheimer disease (AD) patients, and to provide evidence-based reference for optimizing drug selection, dosing strategies, and reimbursement policies in clinical practice.
Why it matters
Galantamine significantly improved cognitive function, living capacity, mental behavior, and global functioning compared with placebo in the reviewed studies. It caused more gastrointestinal side effects than placebo, and the review could not determine whether it was more effective than other acetylcholinesterase inhibitor drugs.
-
Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD).
Why it matters
In this cross-sectional international multi-center study of 1298 plasma samples, p-tau181 showed the best area under the curve for separating Alzheimer's disease from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies, but this discriminative power could not be reproduced using pre-defined cut-offs. The authors conclude that specific cut-offs are needed to maximize diagnostic performance, so this is about diagnosis rather than treatment, cure, or prevention.
-
We investigated whether specific SLEs are associated with AD pathology and neurodegeneration and how these associations differ by gender and education.
Why it matters
This cross-sectional study asked whether stressful life events such as grief and financial strain relate to Alzheimer's pathology and brain changes, and whether this differs by gender and education. It identifies possible social risk factors but does not show that relieving stress prevents or treats the disease.
-
Diet can impact cognitive aging, but comprehensive data from human studies is lacking and the underlying biological mechanisms are still not fully understood.
Why it matters
Using cross-sectional data from dementia-free older adults, this study looked at whether Mediterranean diet and the inflammatory potential of diet were associated with five blood-based Alzheimer's biomarkers. It is about dietary associations with biomarkers, not about treating, curing or preventing the disease.
-
Cerebral amyloid angiopathy (CAA) is driven by vascular Aβ (amyloid-beta) deposition, which can be detected as reduced Aβ species in cerebrospinal fluid (CSF).
Why it matters
This cross-sectional study looked at relationships between cerebrospinal fluid amyloid and tau levels and features of cerebral amyloid angiopathy, a condition caused by amyloid in blood vessels. It is about understanding this vessel condition, not about treating, curing or preventing Alzheimer's disease.
-
Random forest classifier and feature selection procedures were used to select digital biomarkers.
Why it matters
Machine learning models using plasma spectra data distinguished Alzheimer's disease from healthy controls and from other neurodegenerative diseases with areas under the curve ranging from 0.80 to 0.93. This is a diagnostic study and does not test any treatment, cure, or prevention.
-
11 variables were critical in the training phase, including educational level, depression, insomnia, age, Body Mass Index (BMI), medication count, gender, stenting, systolic blood pressure (sbp), neurosis and rapid eye movement.
Why it matters
This cross-sectional study developed a machine learning model using routine clinical variables to help screen for Alzheimer's disease risk in older people. It is a risk-screening tool only and does not test any treatment, cure or prevention.
-
52/100
Recent guidance from the National Alzheimer's Coordinating Center (NACC) recommends remuneration for all Alzheimer's disease (AD) research participants.
Why it matters
This survey describes how Alzheimer's Disease Research Centers remunerate research participants. It does not test any treatment, cure, or prevention for Alzheimer's disease.
-
In vitro and animal studies have suggested that inoculation with herpes simplex virus 1 (HSV-1) can lead to amyloid deposits, hyperphosphorylation of tau, and/or neuronal loss.
Why it matters
Among 182 participants at risk of cognitive decline, researchers examined whether prior herpes simplex virus 1 infection was associated with Alzheimer's biomarkers on PET and blood tests. This is an observational analysis and does not show that preventing or treating the infection affects the disease.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals
- Anosognosia in Alzheimer disease: Disconnection between memory and self-related brain networks
- AD-HOLDER: Alzheimer’s Disease Detection via Machine Learning based Histograms of Light GBM Classifier using MRI and PET Images
- Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia
- Challenges in the identification of underlying pathologies in dementias with predominant behavioral phenotype using laboratory biomarkers
- Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds
- Neighborhood deprivation and mortality among people with Alzheimer's disease and related dementia
- Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease
- Molecular dynamics of amyloid-β transport in Alzheimer's disease: Exploring therapeutic plasma exchange with albumin replacement – Current insights and future perspectives
- Leveraging mHealth and Virtual Reality to Improve Cognition for Alzheimer's Patients: A Systematic Review